Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting
Por:
Guglieri-López B, Pérez-Pitarch A, Porta Oltra B, Ferriols-Lisart F, Royo-Peiró Á and Climente-Martí M
Publicada:
1 ago 2016
Resumen:
To evaluate the effectiveness and toxicity profile of ipilimumab treatment and to examine the cost-effectiveness relation in a real-world sample of patients with metastasic melanoma. This was a multicenter, observational, retrospective cohorts study. To assess the effectiveness and safety of ipilimumab treatment progression-free survival (PFS), overall survival (OS) and adverse events were registered. An economic evaluation was performed and cost-effectiveness ratios (CERs) were calculated. Eleven patients were included, mean age 59 (SD = 11) years. The median PFS was 3.83 months (95% confidence interval 0.98-9.80) and the median OS was 5.15 months (95% confidence interval 1.70-8.48). None of the patients included in the study achieved an objective response. A stable disease was achieved in four (36%) patients. The most commonly reported analytical adverse event was anemia, with all patients developing anemia in any grade. The most severe adverse event was neutropenia (n = 6; 55%), with three patients developing grade 4 neutropenia (3/11; 27%). The total cost of ipilimumab treatment was (sic)483 397, with a median of 43 033 (interquartile range = 9555) euros per patient. The median-based CER was 136 675 (28 539-474 865) euros per progression-free year gained and the median-based CER was 100 112 (23 107-374 893) euros per life-year gained. PFS observed in real-world patients was higher than that reported in clinical trials and OS was lower. The incidence of adverse events was higher. The additional cost per progression-free year gained was similar to (sic)136 675. The data from this study fill an important need for information on the relative value of this treatment in terms of cost-effectiveness. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
Filiaciones:
:
Departments of aPharmacy bMedical Oncology, Dr Peset University Hospital of Valencia cDepartment of Pharmacy, University Clinical Hospital of Valencia, Valencia, Spain
|